These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 18843126)

  • 1. UKPDS and the legacy effect.
    Chalmers J; Cooper ME
    N Engl J Med; 2008 Oct; 359(15):1618-20. PubMed ID: 18843126
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tough glucose reduction necessary in newly diagnosed diabetes].
    Rydén M
    Lakartidningen; 2010 Nov 10-16; 107(45):2810-4. PubMed ID: 21179867
    [No Abstract]   [Full Text] [Related]  

  • 3. [Glycemic control and diabetic complications].
    Yamada Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():604-8. PubMed ID: 15999778
    [No Abstract]   [Full Text] [Related]  

  • 4. 10-year follow-up of intensive glucose control in type 2 diabetes.
    Holman RR; Paul SK; Bethel MA; Matthews DR; Neil HA
    N Engl J Med; 2008 Oct; 359(15):1577-89. PubMed ID: 18784090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes.
    Buysschaert M; Hermans MP
    Acta Clin Belg; 1999 Dec; 54(6):328-33. PubMed ID: 10686705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A summary of the ADVANCE Trial.
    Heller SR;
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S357-61. PubMed ID: 19875581
    [No Abstract]   [Full Text] [Related]  

  • 7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvascular benefits of hypertension and glucose control in type 2 diabetes.
    van Rensburg BW
    Cardiovasc J Afr; 2008; 19(4):179-80. PubMed ID: 18776957
    [No Abstract]   [Full Text] [Related]  

  • 9. Implications of the United Kingdom prospective diabetes study.
    Baldeweg SE; Yudkin JS
    Prim Care; 1999 Dec; 26(4):809-27. PubMed ID: 10523461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined insulin and sulfonylurea therapy for type 2 diabetes mellitus.
    Riddle MC
    Diabetes Res Clin Pract; 1991 Jan; 11(1):3-8. PubMed ID: 2019232
    [No Abstract]   [Full Text] [Related]  

  • 11. Early insulin use in type 2 diabetes: what are the cons?
    Chiasson JL
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S270-4. PubMed ID: 19875563
    [No Abstract]   [Full Text] [Related]  

  • 12. United Kingdom prospective diabetes study: a different perspective.
    Kabadi UM
    Endocr Pract; 2002; 8(1):61-4. PubMed ID: 11939763
    [No Abstract]   [Full Text] [Related]  

  • 13. Type 2 diabetes: target HbA1c of about 7%.
    Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypoglycemia: danger to life of diabetic patients. Higher price for blood sugar adjustment].
    Füessl HS
    MMW Fortschr Med; 2005 Aug; 147(31-32):4-6, 8. PubMed ID: 16128187
    [No Abstract]   [Full Text] [Related]  

  • 15. UKPDS and beyond: into the next millennium. United Kingdom Prospective Diabetes Study.
    Krentz AJ
    Diabetes Obes Metab; 1999 Jan; 1(1):13-22. PubMed ID: 11221807
    [No Abstract]   [Full Text] [Related]  

  • 16. Should we use intensive insulin therapy after oral agent failure in type II diabetes?
    Colwell JA
    Diabetes Care; 1996 Aug; 19(8):896-8. PubMed ID: 8842613
    [No Abstract]   [Full Text] [Related]  

  • 17. (7) Approaches to glycemic treatment.
    American Diabetes Association
    Diabetes Care; 2015 Jan; 38 Suppl():S41-8. PubMed ID: 25537707
    [No Abstract]   [Full Text] [Related]  

  • 18. [Quality of prescription drug use in patients with type 2 diabetes mellitus in Germany].
    Rathmann W; Giani G
    Dtsch Med Wochenschr; 2003 May; 128(21):1183-6. PubMed ID: 12761691
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose control in the UKPDS: what did we learn?
    Gale EA
    Diabet Med; 2008 Aug; 25 Suppl 2():9-12. PubMed ID: 18717972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.